Radiopharmaceuticals/ Nuclear Medicine Market

Radiopharmaceuticals/ Nuclear Medicine Market by Type (Diagnostic (SPECT (Technetium), PET (F-18)), Therapeutic (Beta Emitters (I-131), Alpha Emitters, Brachytherapy(Y-90))), Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2023

Report Code: PH 3590 Jun, 2018, by marketsandmarkets.com

[213 Pages Report] The nuclear medicine market is expected to grow from $3.95 billion in 2018 to $5.26 billion by 2023, at a CAGR of 5.9% from 2018 to 2023. Increasing incidence & prevalence of cancer and cardiovascular diseases and initiatives to lessen the demand-supply gap of Mo-99 are the key factors propelling the growth of this market. The market is expanding with the emergence of new applications and discovery of new medical isotopes. Nuclear Medicine is used in many diagnostic and therapeutic applications such as oncology, cardiology, neurology and other applications. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.

Nuclear Medicine Market Dynamics

Nuclear Medicine Market Drivers

  • Increasing incidence and prevalence of target conditions
  • Alpha radioimmunotherapy-based targeted cancer treatment
  • Initiatives to lessen the demand-supply gap of Mo-99

Nuclear Medicine Market Restraints

  • Short half-life of radiopharmaceuticals

Nuclear Medicine Market Opportunities

  • Use of radiopharmaceuticals in neurological applications

Nuclear Medicine Market Challenges

  • Hospital budget cuts and high equipment prices

Increasing incidence and prevalence of target conditions drives the nuclear medicine market

The rising incidence and prevalence of cancer and cardiovascular diseases (CVD) will be the key factor supporting market growth. Most cases can be prevented through early detection and treatment; nuclear medicine plays a significant role in these areas. According to GLOBOCAN 2012, the global incidence of cancer was 14.1 million (excluding non-melanoma skin cancer) in 2012. In addition, annually ~19.3 million new cases are expected to be detected by 2025. According to the WHO, globally, 17.5 million individuals died from CVD in 2012, representing 31% of overall deaths globally. This figure is expected to reach 23.3 million by 2030.

By driving the overall use and need for nuclear medicine, the rising incidence and prevalence are expected to directly affect market growth.

Nuclear Medicine/Radiopharmaceuticals Market

The following are the major objectives of the Nuclear Medicine Market Research study.

  • To describe and forecast the market, in terms of value, by type, application, procedural volume, and region
  • To describe and forecast the market, by region–Asia Pacific (APAC), Europe, North America, and Rest of the World (RoW) along with their respective countries
  • To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To study the complete value chain of nuclear medicine
  • To analyze opportunities in the market for stakeholders by identifying the high-growth segments of the nuclear medicine ecosystem
  • To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing competitive landscape for market leaders
  • To analyze strategic approaches such as agreements, collaborations, and partnerships; marketing and promotions; and product launches in the market

During this research study, major players operating in the market in various regions have been identified, and their offerings, regional presence, and distribution channels have been analyzed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Factiva, along with primary respondents. The entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) pertaining to the market. The figure below shows the breakdown of the primaries on the basis of the company type, designation, and region considered during the research study.

Nuclear Medicine/Radiopharmaceuticals Market

To know about the assumptions considered for the study, download the pdf brochure

Key players considered in the analysis of the nuclear medicine market are Cardinal Health (US), GE Healthcare (US), Curium (France), Bayer (Germany), Lantheus Medical Imaging (US), Advanced Accelerator Applications (France), and Jubilant Life Sciences (India).

Nuclear Medicine Major Market Developments

  • In 2018, Curium signed an agreement to acquire Cyclopharma’s manufacturing and commercial operations in France.
  • In 2018, AAA received US FDA Approval for LUTATHERA used in the treatment of gastroenteropancreatic neuroendocrine tumors
  • In 2016, Cardinal Health and AAA signed an agreement for the production of AAA’s Netspot. Cardinal Health’s extensive network of radiopharmaceutical manufacturing facilities in the US will prepare and deliver Netspot patient doses to advanced medical imaging sites in key metropolitan areas where high demand is anticipated
  • In 2016, The US Department of Energy’s (DOE) NNSA awarded USD 25.0 million in cooperative agreement funding to General Atomics to complete its project with Nordion and the University of Missouri Research Reactor Center (MURR). The Phase II funding aims to establish a new reliable supply of molybdenum 99 (Mo-99) using Low Enriched Uranium (LEU).
  • In 2015, GE Healthcare partnered with SHINE Medical Technologies (US), a manufacturer of radioisotopes for nuclear medicine. The partnership was aimed at obtaining pharmaceutical-grade Tc-99m from GE Healthcare’s Drytec (Technetium Tc99m Generator) for the production of Sodium Pertechnetate for using Mo-99 produced by SHINE’s innovative process. SHINE is expected to begin commercial production in 2019 using the new process after getting an approval from the US FDA.

Target Audience for Nuclear Medicine Market

  • Manufacturers of nuclear medicine
  • Research organizations and consulting companies
  • Hospitals
  • Diagnostic Laboratories
  • Research institutes and organizations

Nuclear Medicine Market Research Report Scope

Nuclear Medicine Market By Type

  • Diagnostics
    • SPECT Radiopharmaceuticals
      • Technetium-99m
      • Thallium-201
      • Gallium-67
      • Iodine-123
      • Other SPECT Isotopes (In-111 and Xe-133)
    • PET Radiopharmaceuticals
      • Fluorine-18
      • Rubidium-82
      • Other PET Isotopes (C-11, N-13, O-15, Cu-64, I-124, and Ga-68)
  • Therapeutics
    • Beta Emitters
      • Iodine-131
      • Samarium-153
      • Rhenium-186
      • Yttrium-90
      • Lutetium-177
      • Other Beta Emitters (Co-60, Ru-106, Au-198, and Cs-137)
    • Alpha Emitters
      • Iodine-131
    • Brachytherapy Isotopes  
      • Iodine-125
      • Palladium-103
      • Cesium-131
      • Iridium-192
      • Other Brachytherapy Isotopes (Cu-67, Yb-175, Sr-90, P-32, P-33, Ho-166, Re-188, and Sn-117m)

Nuclear Medicine Market By Applications

  • Diagnostics
    • SPECT
      • Cardiology
      • Lymphoma
      • Neurology
      • Thyroid
      • Other SPECT Applications (prostate cancer diagnosis, bone scans, and white cell scans) 
    • PET Radiopharmaceuticals
      • Oncology
      • Cardiology
      • Neurology
      • Other PET Applications
  • Therapeutics
    • Thyroid
    • Bone Metastasis
    • Lymphoma
    • Endocrine Tumors
    • Other Therapeutic Applications

Nuclear Medicine Market By Procedural Volume

  • Diagnostics Market
    • SPECT
    • PET
  • Therapeutics Market
    • Beta Emitters
    • Alpha Emitters
    • Brachytherapy Isotopes

Nuclear Medicine Market By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • APAC
  • Rest of the World

Critical questions which the report answers

  • What are new application areas which the nuclear medicine companies are exploring?
  • Which are the key players in the market and how intense is the competition?

Available Customizations

Based on the given market data, MarketsandMarkets offers customizations in the reports as per the client’s specific requirements. The available customization options are as follows:

Geographic Analysis

  • Further country-wise breakdown of the market in APAC region

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

The overall nuclear medicine market is expected to grow from USD 3.95 billion in 2018 to USD 5.26 billion by 2023, at a CAGR of 5.9% from 2018 to 2023. Increasing incidence & prevalence of cancer and cardiovascular diseases and initiatives to lessen the demand-supply gap of Mo-99 are the key factors propelling the growth of this market.

Nuclear Medicine/Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in nuclear imaging to diagnosis and treat diseases. The nuclear medicine uses radiation to provide diagnostic information about the functioning of a specific organ. Therapy radioisotopes are used to treat medical conditions, especially cancer, using radiation to weaken or destroy particular targeted cells.

Based on type, the market is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals. The diagnostic radiopharmaceuticals have been segmented into SPECT and PET radiopharmaceuticals. PET radiopharmaceuticals have been further segmented into F-18, Ru-82, and other PET isotopes. In 2017, the F-18 segment accounted for the largest share of the nuclear medicine PET radiopharmaceuticals market. F-18 is the most commonly used PET radioisotope owing to its higher half-life (110 minutes) compared to other radioisotopes. F-18 is estimated to account for 98% of the total PET radioisotopes market.

The market in APAC is expected to grow at the highest CAGR during the forecast period. The major factors driving the growth of this regional segment include research initiatives in Japan and the rising installations of PET scanners in India and China.

Nuclear Medicine/Radiopharmaceuticals Market

PET applications in oncology, cardiology, neurology, and other applications (musculoskeletal and rheumatoid arthritis) drive the growth of nuclear medicine market

Oncology

FDG F-18 is used in diagnostic PET imaging to evaluate areas of abnormal glucose metabolism. FDG-PET is more accurate and preferred to conventional imaging for diagnosing various malignancies from staging and restaging to detecting radionecrosis from viable tumors.

FDG F-18 is approved for oncology applications such as staging of cervical, esophageal, gastric, and non-small-cell lung cancer as well as for head and neck carcinomas and lymphoma.

Cardiology

PET radioisotopes are used for diagnosing CVDs. FDG F-18 and Ru-82 are used for diagnosing cardiac disorders such as CAD and left ventricular dysfunction. Ru-82 isotope is a cost-effective alternative to the Tc-99m SPECT isotope, with a preference for Ru-82 in cardiology increasing due to its use in diagnosing CAD. Moreover, Ru-82 offers several advantages over SPECT imaging radioisotopes for the accurate detection of CAD and is thus preferred over Tl-201 SPECT radioisotope.

Neurology

The increasing incidence of AD, epilepsy, and Parkinson’s disease is the major driver for the growth of the PET neurology market. FDG F-18 is majorly used for imaging cerebral glucose consumption. Hence, use of FDG F-18 is increasing for neurology, neurosurgery, and psychiatry applications.

Other Applications

Sensors play an important role in the durability of medical devices and healthcare systems. Nuclear medicines are widely used in applications such as sensing end position, medical mobility equipment, hospital beds, lift chair position, power wheelchair, and mobility scooter. In such applications, nuclear medicines are required to provide enhanced reliability and high sensitivity to ensure patient or user safety.

Critical questions the report answers:

  • Where will all these developments take the industry in the mid to long term?
  • What are the upcoming industry applications for nuclear medicines?

The short half-life of the radioisotopes is a major factor restraining the growth of the market. The expiry of a radiopharmaceutical primarily depends on the half-life of the radioisotope and content of the radionuclide. For example, the radioactivity of F-18 in PET decreases if not used within 110 minutes, while the radioactivity of C-11 decreases within 20 minutes. In SPECT diagnosis, the radioactivity of Tc- 99m is reduced after six hours, while I-123 and In-111 isotopes should be utilized within 13 hours and 67 hours, respectively. Non-utilization of radioisotopes within the prescribed shelf-life causes radiation and chemical decomposition, reducing radiochemical purity to an unacceptable form, which may prove fatal during diagnosis and therapy.

Key players in the nuclear medicine market include Cardinal Health (US), GE Healthcare (US), Curium (France), Bayer (Germany), Lantheus Medical Imaging (US), Advanced Accelerator Applications (France), and Jubilant Life Sciences (India). These players are increasingly undertaking mergers and acquisitions, and product launches to develop and introduce new technologies and products in the market.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 20)
    1.1 Objectives of Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 23)
    2.1 Research Methodology Steps
    2.2 Secondary and Primary Research Methodology
           2.2.1 Secondary Research
                    2.2.1.1 Key Data From Secondary Sources
           2.2.2 Primary Research
                    2.2.2.1 Key Insights From Primary Sources
    2.3 Market Size Estimation Methodology
    2.4 Market Data Validation and Triangulation
    2.5 Assumptions for the Study

3 Executive Summary (Page No. - 31)

4 Premium Insights (Page No. - 34)
    4.1 Nuclear Medicine: Market Overview
    4.2 Geographic Analysis: Nuclear/Radiopharmaceuticals Medicine Market for Pet Applications, By Type (2017)
    4.3 Nuclear/Radiopharmaceuticals Medicine Market Share, By Type, 2018 vs 2023
    4.4 Geographical Snapshot of the Nuclear/Radiopharmaceuticals Medicine Market

5 Market Overview (Page No. - 38)
    5.1 Introduction
           5.1.2 Market Dynamics
           5.1.3 Drivers
                    5.1.3.1 Increasing Incidence and Prevalence of Target Conditions
                    5.1.3.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
                    5.1.3.3 Initiatives to Lessen the Demand-Supply Gap of Mo-99
           5.1.4 Restraints
                    5.1.4.1 Short Half-Life of Radiopharmaceuticals
           5.1.5 Opportunities
                    5.1.5.1 Use of Radiopharmaceuticals in Neurological Applications
           5.1.6 Challenges
                    5.1.6.1 Hospital Budget Cuts and High Equipment Prices

6 Nuclear Medicine Market, By Type (Page No. - 42)
    6.1 Introduction
    6.2 Diagnostic Nuclear Medicine
           6.2.1 Spect Radiopharmaceuticals
                    6.2.1.1 Tc-99m
                    6.2.1.2 Tl-201
                    6.2.1.3 Ga-67
                    6.2.1.4 I-123
                    6.2.1.5 Other Spect Isotopes
           6.2.2 Pet Radiopharmaceuticals
                    6.2.2.1 F-18
                    6.2.2.2 Ru-82
                    6.2.2.3 Other Pet Isotopes
    6.3 Therapeutic Nuclear Medicine
           6.3.1 Alpha Emitters
                    6.3.1.1 Ra-223
           6.3.2 Beta Emitters
                    6.3.2.1 I-131
                    6.3.2.2 Y-90
                    6.3.2.3 Sm-153
                    6.3.2.4 Re-186
                    6.3.2.5 Lu-177
                    6.3.2.6 Other Beta Emitters
           6.3.3 Brachytherapy Isotopes
                    6.3.3.1 I-125
                    6.3.3.2 Ir-192
                    6.3.3.3 Pd-103
                    6.3.3.4 Cs-131
                    6.3.3.5 Other Brachytherapy Isotopes

7 Nuclear Medicine Market, By Application (Page No. - 87)
    7.1 Introduction
    7.2 Diagnostic Applications
           7.2.1 Spect Applications
                    7.2.1.1 Cardiology
                    7.2.1.2 Lymphoma
                    7.2.1.3 Neurology
                    7.2.1.4 Thyroid
                    7.2.1.5 Other Spect Applications
           7.2.2 Pet Applications
                    7.2.2.1 Oncology
                    7.2.2.2 Cardiology
                    7.2.2.3 Neurology
                    7.2.2.4 Other Pet Applications
    7.3 Therapeutic Applications
           7.3.1 Thyroid
           7.3.2 Bone Metastasis
           7.3.3 Lymphoma
           7.3.4 Endocrine Tumors
           7.3.5 Other Therapeutic Applications

8 Nuclear Medicine Market, By Procedural Volume (Page No. - 103)
    8.1 Introduction
    8.2 Diagnostic Procedures
           8.2.1 Spect Radiopharmaceuticals
           8.2.2 Pet Radiopharmaceuticals
    8.3 Therapeutic Procedures
           8.3.1 Beta Emitters
           8.3.2 Alpha Emitters
           8.3.3 Brachytherapy Isotopes

9 Nuclear Medicine Market, By Region (Page No. - 112)
    9.1 Introduction
    9.2 North America
           9.2.1 US
           9.2.2 Canada
    9.3 Europe
           9.3.1 Germany
           9.3.2 France
           9.3.3 UK
           9.3.4 Italy
           9.3.5 Spain
           9.3.6 RoE
    9.4 Asia Pacific
    9.5 Rest of the World

10 Competitive Landscape (Page No. - 173)
     10.1 Overview
     10.2 Market Share Analysis
     10.3 Competitive Scenario
             10.3.1 Agreements, Partnerships, and Contracts
             10.3.2 Product Approvals
             10.3.3 Funding
             10.3.4 Acquisitions
             10.3.5 Expansions
             10.3.6 Other Developments

11 Company Profiles (Page No. - 180)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
     11.1 Cardinal Health
     11.2 Ge Healthcare (A Fully-Owned Subsidiary of General Electric Company)
     11.3 Curium
     11.4 Lantheus Medical Imaging
     11.5 Bayer
     11.6 Bracco Imaging
     11.7 Eczacibasi-Monrol Nuclear Products
     11.8 Nordion (A Subsidiary of Sterigenics International)
     11.9 Advanced Accelerator Applications (Aaa, Acquired By Novartis)

*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. - 203)
     12.1 Discussion Guide
     12.2 Introducing RT: Real-Time Market Intelligence
     12.3 Available Customizations
     12.4 Related Reports
     12.5 Author Details


List of Tables (250 Tables)

Table 1 New Reactors Expected to Open During the Forecast Period
Table 2 Market, By Type, 2016–2023 (USD Million)
Table 3 Nuclear Medicine for Diagnostic Market, By Type, 2016–2023 (USD Million)
Table 4 Nuclear Medicine for Diagnostic Market, By Region, 2016–2023 (USD Million)
Table 5 North America: Nuclear Medicine for Diagnostic Market, By Country, 2016–2023 (USD Million)
Table 6 Europe: Nuclear Medicine for Diagnostic Market, By Country, 2016–2023 (USD Million)
Table 7 Spect Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 8 Spect Radiopharmaceuticals Market, By Region, 2016–2023 (USD Million)
Table 9 North America: Spect Radiopharmaceuticals Market, By Country, 2016–2023 (USD Million)
Table 10 Europe: Spect Radiopharmaceuticals Market, By Country, 2016–2023 (USD Million)
Table 11 Tc-99m Market, By Region, 2016–2023 (USD Million)
Table 12 North America: Tc-99m Market, By Country, 2016–2023 (USD Million)
Table 13 Europe: Tc-99m Market, By Country, 2016–2023 (USD Million)
Table 14 Tl-201 Market, By Region, 2016–2023 (USD Million)
Table 15 North America: Tl-201 Market, By Country, 2016–2023 (USD Million)
Table 16 Europe: Tl-201 Market, By Country, 2016–2023 (USD Million)
Table 17 Ga-67 Market, By Region, 2016–2023 (USD Million)
Table 18 North America: Ga-67 Market, By Country, 2016–2023 (USD Million)
Table 19 Europe: Ga-67 Market, By Country, 2016–2023 (USD Million)
Table 20 I-123 Market, By Region, 2016–2023 (USD Million)
Table 21 North America: I-123 Market, By Country, 2016–2023 (USD Million)
Table 22 Europe: I-123 Market, By Country, 2016–2023 (USD Million)
Table 23 Other Spect Isotopes Market, By Region, 2016–2023 (USD Million)
Table 24 North America: Other Spect Isotopes Market, By Country, 2016–2023 (USD Million)
Table 25 Europe: Other Spect Isotopes Market, By Country, 2016–2023 (USD Million)
Table 26 Pet Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 27 Pet Radiopharmaceuticals Market, By Region, 2016–2023 (USD Million)
Table 28 North America: Pet Radiopharmaceuticals Market, By Country, 2016–2023 (USD Million)
Table 29 Europe: Pet Radiopharmaceuticals Market, By Country, 2016–2023 (USD Million)
Table 30 F-18 Market, By Region, 2016–2023 (USD Million)
Table 31 North America: F-18 Market, By Country, 2016–2023 (USD Million)
Table 32 Europe: F-18 Market, By Country, 2016–2023 (USD Million)
Table 33 Ru-82 Market, By Region, 2016–2023 (USD Million)
Table 34 North America: Ru-82 Market, By Country, 2016–2023 (USD Million)
Table 35 Europe: Ru-82 Market, By Country, 2016–2023 (USD Million)
Table 36 Other Pet Isotopes Market, By Region, 2016–2023 (USD Million)
Table 37 North America: Other Pet Isotopes Market, By Country, 2016–2023 (USD Million)
Table 38 Europe: Other Pet Isotopes Market, By Country, 2016–2023 (USD Million)
Table 39 Nuclear Medicine for Therapeutic Market, By Type, 2016–2023 (USD Million)
Table 40 Nuclear Medicine for Therapeutic Market, By Region, 2016–2023 (USD Million)
Table 41 North America: Nuclear Medicine for Therapeutic Market, By Country, 2016–2023 (USD Million)
Table 42 Europe: Nuclear Medicine for Therapeutic Market, By Country, 2016–2023 (USD Million)
Table 43 Ra-223 Market, By Region, 2016–2023 (USD Million)
Table 44 North America: Ra-223 Market, By Country, 2016–2023 (USD Million)
Table 45 Europe: Ra-223 Market, By Country, 2016–2023 (USD Million)
Table 46 Beta Emitters Market, By Type, 2016–2023 (USD Million)
Table 47 Beta Emitters Market, By Region, 2016–2023 (USD Million)
Table 48 North America: Beta Emitters Market, By Country, 2016–2023 (USD Million)
Table 49 Europe: Beta Emitters Market, By Country, 2016–2023 (USD Million)
Table 50 I-131 Market, By Region, 2016–2023 (USD Million)
Table 51 North America: I-131 Market, By Country, 2016–2023 (USD Million)
Table 52 Europe: I-131 Market, By Country, 2016–2023 (USD Million)
Table 53 Y-90 Market, By Region, 2016–2023 (USD Million)
Table 54 North America: Y-90 Market, By Country, 2016–2023 (USD Million)
Table 55 Europe: Y-90 Market, By Country, 2016–2023 (USD Million)
Table 56 Sm-153 Market, By Region, 2016–2023 (USD Million)
Table 57 North America: Sm-153 Market, By Country, 2016–2023 (USD Million)
Table 58 Europe: Sm-153 Market, By Country, 2016–2023 (USD Million)
Table 59 Re-186 Market, By Region, 2016–2023 (USD Million)
Table 60 North America: Re-186 Market, By Country, 2016–2023 (USD Million)
Table 61 Europe: Re-186 Market, By Country, 2016–2023 (USD Million)
Table 62 Lu-177 Market, By Region, 2016–2023 (USD Million)
Table 63 North America: Lu-177 Market, By Country, 2016–2023 (USD Million)
Table 64 Europe: Lu-177 Market, By Country, 2016–2023 (USD Million)
Table 65 Other Beta Emitters Market, By Region, 2016–2023 (USD Million)
Table 66 North America: Other Beta Emitters Market, By Country, 2016–2023 (USD Million)
Table 67 Europe: Other Beta Emitters Market, By Country, 2016–2023 (USD Million)
Table 68 Brachytherapy Isotopes Market, By Type, 2016–2023 (USD Million)
Table 69 Brachytherapy Isotopes Market, By Region, 2016–2023 (USD Million)
Table 70 North America: Brachytherapy Isotopes Market, By Country, 2016–2023 (USD Million)
Table 71 Europe: Brachytherapy Isotopes Market, By Country, 2016–2023 (USD Million)
Table 72 I-125 Market, By Region, 2016–2023 (USD Million)
Table 73 North America: Iodine-125 Market, By Country, 2016–2023 (USD Million)
Table 74 Europe: Iodine-125 Market, By Country, 2016–2023 (USD Million)
Table 75 Ir-192 Market, By Region, 2016–2023 (USD Million)
Table 76 North America: Ir-192 Market, By Country, 2016–2023 (USD Million)
Table 77 Europe: Ir-192 Market, By Country, 2016–2023 (USD Million)
Table 78 Pd-103 Market, By Region, 2016–2023 (USD Million)
Table 79 North America: Pd-103 Market, By Country, 2016–2023 (USD Million)
Table 80 Europe: Pd-103 Market, By Country, 2016–2023 (USD Million)
Table 81 Cs-131 Market, By Region, 2016–2023 (USD Million)
Table 82 North America: Cs-131 Market, By Country, 2016–2023 (USD Million)
Table 83 Europe: Cs-131 Market, By Country, 2016–2023 (USD Million)
Table 84 Other Brachytherapy Isotopes Market, By Region, 2016–2023 (USD Million)
Table 85 North America: Other Brachytherapy Isotopes Market, By Country, 2016–2023 (USD Million)
Table 86 Europe: Other Brachytherapy Isotopes Market, By Country, 2016–2023 (USD Million)
Table 87 Spect Applications Market, By Type, 2016–2023 (USD Million)
Table 88 Spect Applications Market, By Region, 2016–2023 (USD Million)
Table 89 Cardiology Applications Market, By Region, 2016–2023 (USD Million)
Table 90 Lymphoma Applications Market, By Region, 2016–2023 (USD Million)
Table 91 Neurology Applications Market, By Region, 2016–2023 (USD Million)
Table 92 Thyroid Applications Market, By Region, 2016–2023 (USD Million)
Table 93 Other Spect Applications Market, By Region, 2016–2023 (USD Million)
Table 94 Pet Applications Market, By Type, 2016–2023 (USD Million)
Table 95 Pet Applications Market, By Region, 2016–2023 (USD Million)
Table 96 Oncology Applications Market, By Region, 2016–2023 (USD Million)
Table 97 Cardiology Applications Market, By Region, 2016–2023 (USD Million)
Table 98 Neurology Applications Market, By Region, 2016–2023 (USD Million)
Table 99 Other Pet Applications Market, By Region, 2016–2023 (USD Million)
Table 100 Therapeutic Applications Market, By Type, 2016–2023 (USD Million)
Table 101 Therapeutic Applications Market, By Region, 2016–2023 (USD Million)
Table 102 Thyroid Applications Market, By Region, 2016–2023 (USD Million)
Table 103 Bone Metastasis Applications Market, By Region, 2016–2023 (USD Million)
Table 104 Lymphoma Applications Market, By Region, 2016–2023 (USD Million)
Table 105 Endocrine Applications Market, By Region, 2016–2023 (USD Million)
Table 106 Other Therapeutic Applications Market, By Region, 2016–2023 (USD Million)
Table 107 Nuclear Medicine Procedures Market, By Type, 2016–2023 (Thousand Procedures)
Table 108 Nuclear Medicine Procedures Market, By Region, 2016–2023 (Thousand Procedures)
Table 109 Diagnostic Procedures Market, By Type, 2016–2023 (Thousand Procedures)
Table 110 Diagnostic Procedures Market, By Region, 2016–2023 (Thousand Procedures)
Table 111 Spect Radiopharmaceuticals Market, By Type, 2016–2023 (Thousand Procedures)
Table 112 Spect Radiopharmaceuticals Market, By Type, By Region, 2016–2023 (Thousand Procedures)
Table 113 Pet Radiopharmaceuticals Market, By Type, 2016–2023 (Thousand Procedures)
Table 114 Pet Radiopharmaceuticals Market, By Type, 2016–2023 (Thousand Procedures)
Table 115 Therapeutic Procedures Market, By Type, 2016–2023 (Thousand Procedures)
Table 116 Therapeutic Procedures Market, By Region, 2016–2023 (Thousand Procedures)
Table 117 Beta Emitters Market, By Type, 2016–2023 (Thousand Procedures)
Table 118 Beta Emitters Market, By Region, 2016–2023 (Thousand Procedures)
Table 119 Alpha Emitters Market, By Region, 2016–2023 (Thousand Procedures)
Table 120 Brachytherapy Isotopes Market, By Type, 2016–2023 (Thousand Procedures)
Table 121 Brachytherapy Isotopes Market, By Region, 2016–2023 (Thousand Procedures)
Table 122 Market, By Region, 2016–2023 (USD Million)
Table 123 North America: Market, By Country, 2016–2023 (USD Million)
Table 124 North America: Market, By Type, 2016–2023 (USD Million)
Table 125 North America: Diagnostic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 126 North America: Spect Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 127 North America: Spect Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 128 North America: Pet Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 129 North America: Pet Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 130 North America: Therapeutic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 131 North America: Beta Emitters Market, By Type, 2016–2023 (USD Million)
Table 132 North America: Brachytherapy Isotopes Market, By Type, 2016–2023 (USD Million)
Table 133 North America: Therapeutic Nuclear Medicine Market, By Application, 2016–2023 (USD Million)
Table 134 US: Market, By Type, 2016–2023 (USD Million)
Table 135 US: Diagnostic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 136 US: Spect Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 137 US: Spect Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 138 US: Pet Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 139 US: Pet Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 140 US: Therapeutic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 141 US: Beta Emitters Market, By Type, 2016–2023 (USD Million)
Table 142 US: Brachytherapy Isotopes Market, By Type, 2016–2023 (USD Million)
Table 143 US: Therapeutic Nuclear Medicine Market, By Application, 2016–2023 (USD Million)
Table 144 Canada: Market, By Type, 2016–2023 (USD Million)
Table 145 Canada: Diagnostic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 146 Canada: Spect Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 147 Canada: Spect Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 148 Canada: Pet Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 149 Canada: Pet Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 150 Canada: Therapeutic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 151 Canada: Beta Emitters Market, By Type, 2016–2023 (USD Million)
Table 152 Canada: Brachytherapy Isotopes Market, By Type, 2016–2023 (USD Million)
Table 153 Canada: Therapeutic Nuclear Medicine Market, By Application, 2016–2023 (USD Million)
Table 154 Europe: Market, By Country, 2016–2023 (USD Million)
Table 155 Europe: Market, By Type, 2016–2023 (USD Million)
Table 156 Europe: Diagnostic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 157 Europe: Spect Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 158 Europe: Spect Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 159 Europe: Pet Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 160 Europe: Pet Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 161 Europe: Therapeutic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 162 Europe: Beta Emitters Market, By Type, 2016–2023 (USD Million)
Table 163 Europe: Brachytherapy Isotopes Market, By Type, 2016–2023 (USD Million)
Table 164 Europe: Therapeutic Nuclear Medicine Market, By Application, 2016–2023 (USD Million)
Table 165 Germany: Market, By Type, 2016–2023 (USD Million)
Table 166 Germany: Diagnostic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 167 Germany: Spect Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 168 Germany: Spect Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 169 Germany: Pet Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 170 Germany: Pet Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 171 Germany: Therapeutic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 172 Germany: Beta Emitters Market, By Type, 2016–2023 (USD Million)
Table 173 Germany: Brachytherapy Isotopes Market, By Type, 2016–2023 (USD Million)
Table 174 Germany: Therapeutic Nuclear Medicine Market, By Application, 2016–2023 (USD Million)
Table 175 France: Market, By Type, 2016–2023 (USD Million)
Table 176 France: Diagnostic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 177 France: Spect Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 178 France: Spect Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 179 France: Pet Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 180 France: Pet Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 181 France: Therapeutic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 182 France: Beta Emitters Market, By Type, 2016–2023 (USD Million)
Table 183 France: Brachytherapy Isotopes Market, By Type, 2016–2023 (USD Million)
Table 184 France: Therapeutic Nuclear Medicine Market, By Application, 2016–2023 (USD Million)
Table 185 UK: Market, By Type, 2016–2023 (USD Million)
Table 186 UK: Diagnostic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 187 UK: Spect Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 188 UK: Spect Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 189 UK: Pet Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 190 UK: Pet Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 191 UK: Therapeutic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 192 UK: Beta Emitters Market, By Type, 2016–2023 (USD Million)
Table 193 UK: Brachytherapy Isotopes Market, By Type, 2016–2023 (USD Million)
Table 194 UK: Therapeutic Nuclear Medicine Market, By Application, 2016–2023 (USD Million)
Table 195 Italy: Market, By Type, 2016–2023 (USD Million)
Table 196 Italy: Diagnostic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 197 Italy: Spect Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 198 Italy: Spect Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 199 Italy: Pet Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 200 Italy: Pet Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 201 Italy: Therapeutic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 202 Italy: Beta Emitters Market, By Type, 2016–2023 (USD Million)
Table 203 Italy: Brachytherapy Isotopes Market, By Type, 2016–2023 (USD Million)
Table 204 Italy: Therapeutic Nuclear Medicine Market, By Application, 2016–2023 (USD Million)
Table 205 Spain: Market, By Type, 2016–2023 (USD Million)
Table 206 Spain: Diagnostic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 207 Spain: Spect Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 208 Spain: Spect Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 209 Spain: Pet Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 210 Spain: Pet Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 211 Spain: Therapeutic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 212 Spain: Beta Emitters Market, By Type, 2016–2023 (USD Million)
Table 213 Spain: Brachytherapy Isotopes Market, By Type, 2016–2023 (USD Million)
Table 214 Spain: Therapeutic Nuclear Medicine Market, By Application, 2016–2023 (USD Million)
Table 215 RoE: Market, By Type, 2016–2023 (USD Million)
Table 216 RoE: Diagnostic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 217 RoE: Spect Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 218 RoE: Spect Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 219 RoE: Pet Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 220 RoE: Pet Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 221 RoE: Therapeutic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 222 RoE: Beta Emitters Market, By Type, 2016–2023 (USD Million)
Table 223 RoE: Brachytherapy Isotopes Market, By Type, 2016–2023 (USD Million)
Table 224 RoE: Therapeutic Nuclear Medicine Market, By Application, 2016–2023 (USD Million)
Table 225 Asia Pacific: Market, By Type, 2016–2023 (USD Million)
Table 226 Asia Pacific: Diagnostic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 227 Asia Pacific: Spect Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 228 Asia Pacific: Spect Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 229 Asia Pacific: Pet Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 230 Asia Pacific: Pet Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 231 Asia Pacific: Therapeutic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 232 Asia Pacific: Beta Emitters Market, By Type, 2016–2023 (USD Million)
Table 233 Asia Pacific: Brachytherapy Isotopes Market, By Type, 2016–2023 (USD Million)
Table 234 Asia Pacific: Therapeutic Nuclear Medicine Market, By Application, 2016–2023 (USD Million)
Table 235 RoW: Market, By Type, 2016–2023 (USD Million)
Table 236 RoW: Diagnostic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 237 RoW: Spect Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 238 RoW: Spect Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 239 RoW: Pet Radiopharmaceuticals Market, By Type, 2016–2023 (USD Million)
Table 240 RoW: Pet Radiopharmaceuticals Market, By Application, 2016–2023 (USD Million)
Table 241 RoW: Therapeutic Nuclear Medicine Market, By Type, 2016–2023 (USD Million)
Table 242 RoW: Beta Emitters Market, By Type, 2016–2023 (USD Million)
Table 243 RoW: Brachytherapy Isotopes Market, By Type, 2016–2023 (USD Million)
Table 244 RoW: Therapeutic Nuclear Medicine Market, By Application, 2016–2023 (USD Million)
Table 245 Agreements, Partnerships, and Contracts (2015–2018)
Table 246 Product Approvals (2015–2018)
Table 247 Funding (2015–2018)
Table 248 Acquisitions (2015–2018)
Table 249 Expansions (2015–2018)
Table 250 Other Developments (2015–2018)


List of Figures (34 Figures)

Figure 1 Global Market: Research Methodology
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Bottom-Up Approach
Figure 4 Top-Down Approach
Figure 5 Research Design
Figure 6 Data Triangulation Methodology
Figure 7 Market, By Type, 2018 vs 2023 (USD Million)
Figure 8 Nuclear Medicine Market for Spect Applications, By Type, 2018 vs 2023 (USD Million)
Figure 9 Nuclear Medicine Market for Pet Applications, By Type, 2018 vs 2023 (USD Million)
Figure 10 Rising Incidence & Prevalence of Cancer & Cardiovascular Diseases—Key Factor Supporting Market Growth During the Forecast Period
Figure 11 Oncology Segment Dominated the Market for Pet Applications in 2017
Figure 12 Diagnostics Segment Will Continue to Dominate the Market in 2023
Figure 13 Asia Pacific to Witness the Highest Growth in the Market During the Forecast Period
Figure 14 Drivers, Restraints, Opportunities, and Challenges
Figure 15 Diagnostic Nuclear Medicine Segment Commanded the Largest Share of the Market in 2017
Figure 16 Pet Radiopharmaceuticals to Register the Highest Growth Rate During the Forecast Period
Figure 17 Alpha Emitters Will Continue to Dominate the Therapeutic Nuclear Medicine Market During the Forecast Period
Figure 18 Geographical Snapshot of the Market
Figure 19 Thyroid Segment is Expected to Register the Highest CAGR in the Spect Applications Market During the Forecast Period
Figure 20 Oncology Applications Segment is Expected to Grow at the Highest CAGR in the Pet Applications Market During the Forecast Period
Figure 21 Endocrine Tumors Application Segment is Expected to Register the Highest CAGR in the Therapeutic Applications Market During the Forecast Period
Figure 22 Nuclear Medicine Procedures Market, By Type, 2018 vs 2023 (Thousand Procedures)
Figure 23 North America to Dominate the Market in 2018
Figure 24 North America: Market Snapshot
Figure 25 Europe: Market Snapshot
Figure 26 Asia Pacific: Market Snapshot
Figure 27 RoW: Market Snapshot
Figure 28 Key Developments in the Market, 2015–2018
Figure 29 Market Share Analysis, By Key Players, 2017
Figure 30 Cardinal Health: Company Snapshot (2017)
Figure 31 GE Healthcare: Company Snapshot (2017)
Figure 32 Lantheus Medical Imaging: Company Snapshot (2017)
Figure 33 Bayer: Company Snapshot (2017)
Figure 34 Advanced Accelerator Applications: Company Snapshot (2016)


Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
PH 3590
Published ON
Jun, 2018
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Radiopharmaceuticals/ Nuclear Medicine Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved